Azathioprine hypersensitivity syndrome manifesting as subcutaneous Sweet syndrome and acute pancreatitis. (21st September 2022)

• Record Type: Journal Article
• Authors: Thomas, Jacob L.; Tee, Michael W.; Harp, Joanna; Magro, Cynthia
• Is Part Of: Journal of cutaneous pathology. Volume 50:Number 2(2023)
• Page Start: 127
• Page End: 130
• Publication Date: 2022-09-21
• Subjects: azathioprine -- contraception -- immunosuppressive therapy -- pancreatitis -- Sweet syndrome; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.14315
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract: Azathioprine (AZA) is a commonly used immunosuppressive therapy that has been implicated in a number of cutaneous and systemic inflammatory reactions. Initiation of AZA has been associated with a hypersensitivity syndrome manifesting as acute pancreatitis and Sweet syndrome. Subcutaneous Sweet syndrome is a rare variant of Sweet syndrome where the dominant localization of inflammation is within the subcutaneous fat; it is commonly associated with underlying myeloproliferative disease. However, it has not been reported in the literature as a cutaneous manifestation of AZA hypersensitivity syndrome. We present a unique case of acute pancreatitis and biopsy‐proven subcutaneous Sweet syndrome following the initiation of AZA with resolution upon discontinuation.